Wild orcas will sometimes offer food to humans
'Orcas often share food with each other—it's a prosocial activity and a way that they build relationships with each other,' Jared Towers, a study lead author and executive director of the British Columbia-based research organization Bay Cetology said in a statement. 'That they also share with humans may show their interest in relating to us as well.'
Towers collaborated with Vanessa Prigollini at Mexico's Marine Education Association along with killer whale expert Ingrid Visser at the Orca Research Trust in New Zealand to collect incidents of the apex predators voluntarily meeting people. They ultimately confirmed 34 events spanning the last two decades. In total, 11 instances involved orcas approaching humans swimming in water, 21 cases occurred while people were on boats, and another two examples were recorded from shore.
However, the researchers didn't simply take witnesses at their word. In order to be included in the study, a potential documentation needed to meet stringent criteria after reviewing any video and photographic evidence, as well as subject interviews. In each event, the orcas must have approached humans of their own volition, then dropped an item in front of them. The whales varied in both age and sex, but all except one appeared to wait for a reaction. In some cases, they even reattempted their food offers—a mix of fish, mammals, invertebrates, birds, as well as one reptile and one piece of seaweed.
'Offering items to humans could simultaneously include opportunities for killer whales to practice learned cultural behavior, explore or play and in so doing learn about, manipulate or develop relationships with us,' the researchers wrote in the study. 'Giving the advanced cognitive abilities and social, cooperative nature of this species, we assume that any or all these explanations for, and outcomes of such behavior are possible.'
The team added these may be the first in-depth descriptions of non-domesticated animals behaving in ways that are usually reserved for household pets like cats and dogs. They may also mark the first accounts of wild predators purposefully employing prey and other objects to 'directly explore human behavior.' If true, these instances 'may highlight the evolutionary convergence of intellect between highest order primates and dolphins.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibody Preclinical results demonstrate strong anti-tumor activity and favorable tolerability profile Phase 1 clinical trial evaluating ZW251 in hepatocellular carcinoma (HCC) expected to be initiated in 2025 VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW251, a novel glypican-3 (GPC3)-targeted ADC incorporating the company's proprietary topoisomerase 1 inhibitor (TOPO1i) payload, ZD06519, for the treatment of HCC. HCC is the most common type of primary liver cancer, with GPC3 expressed in over 75% of cases1. ZW251 is a potential first-in-class ADC engineered to selectively target GPC3. It is composed of a humanized IgG1 antibody conjugated to a novel camptothecin-based TOPO1i using a validated peptide cleavable linker. A drug-antibody-ratio (DAR) of four was selected for ZW251 as a lower DAR potentially could unlock a broader range of dose levels, a potential benefit as HCC patients are commonly challenged by impairment of liver function as a result of chronic liver disease and cirrhosis. In preclinical studies, ZW251 demonstrated strong activity in a range of HCC models, including a range of patient derived xenografts exhibiting a breadth of GPC3 expression and noteworthy tolerability in non-human primate toxicology studies at doses up to 120 mg/kg. 'This advancement marks the second ADC from our wholly-owned pipeline, utilizing our proprietary TOPO1i payload, to progress into clinical development, reinforcing confidence in our approach,' said Paul Moore, Ph.D., Chief Scientific Officer of Zymeworks. 'Like ZW191, which is currently in clinical trials, ZW251 utilizes the same payload paired with an optimized antibody. Our observations with ZW191 in the clinic to date provide a strong foundation as we initiate clinical development of this second ADC. With its novel design, unique mechanism of action, and promising preclinical activity, ZW251 offers the potential to meaningfully improve upon the current standard of care for HCC either as a monotherapy or in combination.' We plan to commence Phase 1 clinical studies for ZW251 in 2025. About Zymeworks Inc. Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval and China' s NMPA granted conditional approval for zanidatamab to treat adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. The European Commission (EC) has granted conditional marketing authorization for Ziihera® as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+) biliary tract cancer previously treated with at least one prior line of systemic therapy. Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive biliary tract cancer in the U.S., Europe, and China. In addition, zanidatamab is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are actively recruiting and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks' pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit and follow @ZymeworksInc on X. Cautionary Note Regarding Forward-Looking StatementsThis press release includes 'forward-looking statements' or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the efficacy and safety of zanidatamab and Zymeworks' product candidates; ongoing clinical studies and regulatory reviews; the potential addressable market of zanidatamab and Zymeworks' product candidates; the timing of and results of interactions with regulators; Zymeworks' clinical development of its product candidates and enrollment in its clinical trials; the timing and status of ongoing and future studies, clinical trials and the related data; expectations regarding future regulatory filings and approvals and the timing thereof; potential safety profile and therapeutic effects of zanidatamab and Zymeworks' product candidates; and the commercial potential of technology platforms and product candidates. When used herein, words such as 'plan', 'believe', 'expect', 'may', 'anticipate', 'potential', 'will', 'intend', 'continues', 'progress', and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: clinical trials, including any required confirmatory trials, may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; conditional regulatory approval may be withdrawn or revoked if any of Zymeworks' or its partners' product candidates fail to satisfy the requirements of any such conditional regulatory approvals; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty and new policies implemented under the current administration, including executive orders, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf; zanidatamab and Zymeworks' product candidates may not be successfully commercialized; clinical trials and any future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under 'Risk Factors' in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at and Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. Contacts: Investor Inquiries:Shrinal InamdarSenior Director, Investor Relations(604) 678-1388ir@ Media Inquiries:Diana PapoveSenior Director, Corporate Communications(604) 678-1388media@ _______________________ 1 Wang HL et al., Arch Pathol Lab Med 2008.
Yahoo
4 hours ago
- Yahoo
First Hydrogen Expands SMR Design Collaboration with Renewable Thermal Laboratory at the University of Alberta to Advance Nuclear SMR Technology
Vancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - First Hydrogen Corp. (TSXV: FHYD) (OTC Pink: FHYDF) (FSE: FIT) ("FIRST HYDROGEN" or the "Company") is pleased to announce, further to the Company's news release of June 9, 2025, the addition of Small Modular Nuclear Reactor (SMR) design in the collaboration with Professor Muhammad Taha Manzoor from the University of Alberta. The project will focus on fuel reactor materials, reactor design and reactor design optimization taking into consideration the growth of artificial intelligence (AI) data centres. SMRs offer some key benefits compared to traditional nuclear reactors: SMRs are compact and can be installed in remote locations, can be factory-fabricated and shipped to the site, scale incrementally with demand, are safer due to its simplified designs, potentially use fuels other than enriched uranium, longer periods between refueling and have lower upfront costs. Canada is globally recognized for its exceptional nuclear expertise, notably through its renowned CANDU (Canadian Deuterium-Uranium) reactors, widely considered among the safest and most reliable nuclear technologies in the world. Leveraging SMRs, First Hydrogen aims to deliver stable, cost-effective, and efficient process for producing green hydrogen, addressing the growing demand for clean energy solutions worldwide. By integrating advanced nuclear technology with green hydrogen production, the Company is positioned to meet rising global demand for clean energy. The Company is currently reviewing potential sites in Canada and Europe. First Hydrogen believes Canada's strong nuclear expertise and proven track record position its technologies as a leading choice for SMR development. Prime Minister Carney has endorsed SMR technology as crucial to ensuring energy independence and transforming the country into a leading energy superpower. As per the Government of Canada (January 8, 2025), there are currently five nuclear power plants situated in three provinces housing 22 nuclear power reactors. These power plants produce 15% of Canada's electricity. Notable Canadian SMR projects include Ontario Power Generation's (OPG) Darlington SMR initiative aiming to build four reactors, New Brunswick's focus on fourth-generation SMRs including ARC Clean Energy's development at Point Lepreau, and Saskatchewan's active exploration into SMRs for grid-scale power generation. Goldman Sachs projects that artificial intelligence will drive a 160% increase in data center power demand by 2030, reshaping global energy consumption. Unlike previous years when efficiency improvements offset growing workloads, AI's heavy computational needs-like a ChatGPT query using nearly 10× the electricity of a Google search-are overwhelming those gains. Currently responsible for about 1-2% of global electricity, data centers could reach 3-4% by decade's end, with AI accounting for 19% of that demand by 2028. U.S. utilities needing $50 billion in new generation capacity and Europe facing over $1.7 trillion in grid and renewable investments. (AI is poised to drive 160% increase in data center power demand | Goldman Sachs) Dr. Manzoor commented, "We are pleased to see our collaboration with First Nuclear expanding, as they broaden their small modular reactor (SMR) approach by integrating design elements and committing additional support to this challenging yet exciting endeavor. SMR design is a complex, multidisciplinary problem that requires assembling a diverse team of experts. We look forward to deepening our partnerships across Canadian academia and industry in the years ahead." About First Nuclear Corp. ( First Hydrogen Corp. is committed to developing and commercializing advanced clean energy solutions, including green hydrogen produced by state-of-the-art Small Modular Reactors. The Company aims to provide scalable, sustainable, and economically viable alternatives to meet global climate goals and enhance energy security. About First Hydrogen Corp. ( First Hydrogen Corp. is a Vancouver, Montreal, Germany and London UK-based company focused on zero-emission vehicles, green hydrogen production and distribution. The Company has designed and built two hydrogen- fuel-cell-powered light commercial vehicles ("FCEV"). The FCEV are road-legal in the United Kingdom (excluding Northern Ireland) with 6,000 km of testing completed and have achieved a range of 630+ kilometres on a single refueling. The vehicles have successfully been trialled in real-world conditions with fleet operators in the United Kingdom. On behalf of the Board of Directors of FIRST HYDROGEN CORP."Balraj Mann"Chairman & Chief Executive Officer Contact:Balraj MannFirst Hydrogen Corp.604-601-2018investors@ Cautionary Note Regarding Forward-Looking Statements This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of First Hydrogen, and includes statements about, among other things, future developments and the future operations, strengths and strategies of First Hydrogen. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results. The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for First Hydrogen's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions. The forward-looking information contained in this news release represents the expectations of First Hydrogen as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. First Hydrogen undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICE PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE To view the source version of this press release, please visit Sign in to access your portfolio
Newsweek
a day ago
- Newsweek
MrBeast Makes Astronomer Joke After Gwyneth Paltrow Video
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. MrBeast, who was recently named the top content creator in the world by Forbes, has reacted to one of the year's most viral stories, the Astronomer Coldplay "kiss-cam scandal." In a post on X, formerly Twitter, MrBeast responded to the company's recent marketing video, which featured Gwyneth Paltrow. Newsweek has reached out to a representative for MrBeast via email for comment. Why It Matters MrBeast's social media post comes after a split-second clip of Astronomer CEO Andy Byron and his colleague Kristin Cabot was shared on social media and promptly broke the internet. The video, first shared by instaagraace on TikTok, has been viewed over 128 million times as of time of writing. Left, MrBeast speaks onstage during YouTube Brandcast 2025 at David Geffen Hall in New York City on May 14, 2025. Right, Gwyneth Paltrow attends the 2025 Breakthrough Prize Ceremony at Barker Hangar in Santa Monica,... Left, MrBeast speaks onstage during YouTube Brandcast 2025 at David Geffen Hall in New York City on May 14, 2025. Right, Gwyneth Paltrow attends the 2025 Breakthrough Prize Ceremony at Barker Hangar in Santa Monica, California, on April 5, 2025. More Taylor Hill/FilmMagic/for YouTube In the clip, the jumbotron lands on the pair and they promptly sprang apart. Coldplay's lead singer Chris Martin, says: "Either they're having an affair or they're just really shy." The pair were later identified as Byron, CEO of the tech firm Astronomer, and Cabot, the company's head of Human Resources. Both have now resigned. What To Know On July 26, Astronomer shared a light-hearted marketing video which capitalizes on the attention that has been brought to the company since the now infamous Coldplay canoodling. The video features Paltrow, Martin's Oscar-winning ex-wife, as a "very temporary spokesperson." MrBeast, real name Jimmy Donaldson, responded to this on X. In a post that has been viewed over 230,000 times, he wrote, "Can I be CEO." Astronomer's board of directors have announced that they will start a formal search for their new chief executive. Company co-founder Pete DeJoy has taken over as interim CEO. He said on Monday that Astronomer has faced an "unusual and surreal" amount of attention in recent days. Astronomer is a New York-based company that helps companies develop, grow, and analyze products using artificial intelligence. MrBeast, whose YouTube channel boasts over 416 million subscribers, is the owner of multiple companies, including Feastables and MrBeast Burger. He has previously shared posts on social media expressing interest in buying the social media platform X from Elon Musk. In June, as part of their list of Top Content Creators, Forbes reported that MrBeast had earnings of $85 million. Back in 2022, Forbes reported the 27-year-old could become the world's "first YouTuber billionaire," reporting at the time that he had a net worth of $500 million. What People Are Saying An Astronomer spokesperson previously told Newsweek in a statement: "Astronomer is committed to the values and culture that have guided us since our founding. Our leaders are expected to set the standard in both conduct and accountability, and recently, that standard was not met." What's Next The search for Astronomer's new CEO is ongoing.
